ReviewCurrent oncology reports2016
Immunotherapy as a Potential Treatment for Chordoma: a Review.
Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- A clinical analysis of 19 cases of chordomas with poor differentiation treated using diverse therapeutic modalities.Discover oncology · 2025Article
- Gas Plasma Technology and Immunogenic Cell Death: Implications for Chordoma Treatment.Cancers · 2025Review
- Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review.Journal of clinical medicine · 2024Review
- Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review.Cancers · 2022Review
- Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies.Frontiers in oncology · 2022Article
- Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.Frontiers in immunology · 2021Review
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- Advances in the management of primary bone sarcomas of the skull base.Journal of neuro-oncology · 2020Review
- Fingolimod inhibits proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signalling.Bioscience reports · 2020Article
- Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.Journal of neuro-oncology · 2019Article
- Clinicopathologic characteristics of poorly differentiated chordoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Lymphocyte-Related Inflammation and Immune-Based Scores Predict Prognosis of Chordoma Patients After Radical Resection.Translational oncology · 2018Article
- Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment.Neurosurgical focus · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoma is a locally aggressive primary malignancy of the axial skeleton. The gold standard for treatment is en bloc resection, with some centers now advocating for the use of radiation to help mitigate the risk of recurrence. Local recurrence is common, and salvaging local failures is quite difficult. Chemotherapy has been ineffective and small molecule targeted therapy has had only marginal benefits in small subsets of patients with rare tumor phenotypes or refractory disease. Recent successes utilizing immunotherapy in a variety of cancers has led to a resurgence of interest in modifying the host immune system to develop new ways to treat tumors. This review will discuss these studies and will highlight the early studies employing immune strategies for the treatment of chordoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.